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This chapter will focus on the role of microRNAs (miRs) in regulating the actions of opioid
drugs through the opioid receptors. Opioids, such as morphine, are analgesics that are
used for treating many forms of acute and chronic pain. However, their chronic use is lim-
ited by undesirable effects such as opioid tolerance. The μ opioid receptor (MOR) is the
primary receptor responsible for opioids’ analgesia and antinociceptive tolerance.The long
3′-untranslated region (3′-UTR) ofMORmRNA is of great interest since this regionmay con-
tain elements for the post-transcriptional regulation of receptor expression, such as altering
the stability of mRNA, inﬂuencing translational efﬁciency, and controlling mRNA transport.
MicroRNAs are small non-coding RNA molecules that exert their functions through base-
pairing with partially complementary sequences in the 3′-UTR of target mRNAs, resulting
in decreased polypeptide formation from those mRNAs. Since the discovery of the ﬁrst
miR, lin-4 in Caenorhabditis elegans, hundreds of miRs have been identiﬁed from humans
to viruses, which have provided a crucial and pervasive layer of post-transcriptional gene
regulation. The nervous system is a rich source of miR expression, with a diversity of miR
functions in fundamental neurobiological processes including neuronal development, plas-
ticity, metabolism, and apoptosis. Recently, the let-7 family of miRs is found to be a critical
regulator of MOR function in opioid tolerance. Let-7 is the ﬁrst identiﬁed human miR. Its
family members are highly conserved across species in sequence and function. In the
review, we will present a brief review of the opioid receptors, their regulation, and opioid
tolerance as well as an overview of miRs and a perspective how miRs may interact with
MOR and serve as a regulator of opioid tolerance.
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INTRODUCTION
Since ﬁrst isolated from opium poppy in the early nineteenth cen-
tury, morphine and related opioids remain as the most powerful
analgesics to treat many forms of acute and chronic pain. How-
ever, repeated and prolonged use of opioids leads to tolerance, of
which, the analgesic tolerance is the most problematic that can
lead to therapeutic failure (i.e., inadequate pain control; McQuay,
1999). In some cases, even the highest tolerable dose of an opioid
cannot achieve the desirable analgesic effect in patients (Wang and
Wang, 2006; Harden, 2008). Development of opioid tolerance not
only limits the analgesic efﬁcacy, but the increased doses of opioids
in order to counter tolerance exacerbate another problem, namely
opioid addiction that is a signiﬁcant medical and public health
problem. Extensive efforts have beenmade to elucidate themecha-
nisms underlying opioid tolerance anddrug addiction (Kieffer and
Evans, 2002). Increasing evidence implicates the contribution of
transcriptional and epigenetic regulation in opioid tolerance and
drug addiction, such as activation and inhibition of transcription
factors (Carlezon et al., 2005; Zachariou et al., 2006),modiﬁcation
of chromatin and DNA structure (Renthal et al., 2008; Guo et al.,
2011), and induction of non-coding RNAs including microRNAs
(Pietrzykowski, 2011; Robison and Nestler, 2011).
MicroRNAs (miRs) are small non-coding RNA molecules that
repress target gene expression through base-pairing with partially
complementary sequences in the 3′-untranslated region (3′-UTR)
of target mRNAs. Owing to recent cloning, sequencing, and com-
putational efforts, the numbers of known miRs has been rapidly
increasing, and to date, there are a total of 21,643 mature miRs
found across 103 species, of which 1921miRs are found in humans
(miRBase Release 18.0, November 20111). With the emerging
identiﬁcation of miRs from humans to viruses, a crucial and per-
vasive layer of post-transcriptional gene regulation by miRs has
been elucidated (Ambros, 2004; Taft et al., 2010). It is generally
accepted that miRs serve as an important class of epigenetic regu-
lators that participate in a variety of cellular activities. In respect to
their diverse functions, miRs play an integral role in fundamental
neurobiological processes including neuronal development, plas-
ticity, metabolism, and apoptosis (Kosik, 2006). As one form of
long-lasting synaptic plasticity, opioid tolerance is a particularly
interesting research area to study miR-mediated cellular adapta-
tion. In this review, we summarize recent ﬁndings on miRs in
opioid tolerance,with a focus on the role of let-7miRs in regulating
opioid tolerance.
Mu OPIOID RECEPTOR AND OPIOID TOLERANCE
The μ opioid receptor (MOR), a member of the G-protein cou-
pled receptor superfamily, is the primary receptor responsible for
1http://microrna.sanger.ac.uk/sequences
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opioids’ analgesia and antinociceptive tolerance (Matthes et al.,
1996; Sora et al., 1997). Opioid tolerance may be result from opi-
oid receptor desensitization and trafﬁcking, which include opioid
receptor down-regulation, internalization, and uncoupling from
G-proteins due to chronic exposure to opioid agonists (Bailey and
Connor, 2005; Martini and Whistler, 2007; Koch and Hollt, 2008;
Lopez-Gimenez andMilligan, 2010). Receptor down-regulation as
one of mechanisms contributing to opioid tolerance has been pre-
viously proposed (Davis et al., 1979; Tao et al., 1987; Bhargava and
Gulati, 1990; Bernstein andWelch,1998;Diaz et al., 2000). Chronic
morphine treatment produced a marked decrease in brain MOR
density (Davis et al., 1979; Tempel et al., 1988). Down-regulation
of the high-afﬁnityMOR site in rats has also been reported follow-
ing continuous infusion of morphine (i.t.; Wong et al., 1996) or
etorphine (s.c.; Tao et al., 1987). Morphine-induced MOR down-
regulation was also observed in SH-SY5Y cells, with or without
differentiation (Zadina et al., 1993). In addition to receptor down-
regulation, chronic treatment with morphine has been shown to
signiﬁcantly reduceMOR-signaling in sensory neurons and brain-
stem nuclei (Sim et al., 1996; Johnson et al., 2006), which are in
agreement with the ﬁndings that reduced receptor number and
resultant reduced MOR-signaling contribute to opioid tolerance.
On the other hand, there have been reports that MOR expression
was not altered (Dum et al., 1979) or even up-regulated (Lewis
et al., 1984) in the brain by various opioids. Some of the dis-
crepancies may be caused by uncontrolled variables (e.g., different
opioids, doses, methods of opioid treatments, anatomical regions,
and times samples were taken, integrality of tissue samples before
assays, and opioid receptor subtypes studied), as well as detec-
tion methods. It has been suggested that MOR down-regulation
is agonist selective and depends on the agonist’s intrinsic efﬁcacy
(Nishino et al., 1990; Chakrabarti et al., 1997; Chan et al., 1997;
Koch and Hollt, 2008). The purity and selectivity of radiolabeled
ligands – a problem not only for some early studies, but also in
more recent reports employing questionable materials – used in
studies are the other potential culprits for conﬂicting ﬁndings.
DIRECT INTERACTION BETWEEN let-7 FAMILY miRs AND
MOR
The long 3′-UTR of MOR mRNA (Ide et al., 2005; Han et al.,
2006) suggests that this region may contain physiologically rele-
vant elements for regulating receptor expression by mechanisms
such as miR targeting. Indeed, early research on 3′-UTR of human
MORmRNA suggested thatMOR expression was increased after a
712-bp segment, immediately downstream of the stop codon, was
removed (Zollner et al., 2000). Comparative bioinformatics pre-
dicted potentialmiRs thatmay interactwith the human andmouse
MOR (Table 1). Let-7 family of miRs was identiﬁed as a top candi-
date according to the number of putative target sites and alignment
pattern. Our group experimentally validated the in silico predic-
tion that members of the let-7 miR family can interact with the
3′-UTRofMORmRNAat the predicted positions (He et al., 2010).
Furthermore, downregulating let-7 with speciﬁc LNA-modiﬁed
antisense oligodeoxynucleotides (LNA-let-7-AS) was found to
increase MOR expression in SH-SY5Y cells, a human neuroblas-
toma cell line, suggesting that (1) MOR is a target of let-7; (2)
expression of MOR is under constitutive suppression by let-7.
Table 1 | MicroRNA targets predicted by miRanda
(http://www.microrna.org/microrna/getGeneForm.do) and ranked
according to the alignment scores.
miRNA Query target
sites
Alignment
score
PhastCons
score
HUMAN OPRM1 3′-UTR
hsa-miR-600 291 169 0.666615
hsa-miR-384 83 157 0.619627
hsa-miR-105 172 156 0.619627
hsa-let-7b 381 154 0.607749
hsa-let-7c 383 154 0.607749
hsa-let-7g 386 154 0.607749
hsa-let-7i 386 154 0.607749
hsa-miR-1272 261 154 0.643121
hsa-miR-642 151 154 0.619627
hsa-miR-98 386 154 0.607749
hsa-let-7f 383 153 0.607749
hsa-let-7d 386 152 0.607749
hsa-miR-18a 401 152 0.607749
hsa-miR-198 124 152 0.619627
hsa-let-7a 385 151 0.607749
hsa-miR-302a 169 151 0.619627
hsa-miR-1324 286 150 0.666615
hsa-miR-192 102 150 0.619627
hsa-miR-215 102 150 0.619627
hsa-miR-648 144 150 0.619627
hsa-miR-18b 399 149 0.607749
hsa-miR-383 389 149 0.607749
hsa-miR-526b 52 149 0.619627
hsa-miR-659 233 149 0.619627
hsa-let-7e 385 147 0.607749
hsa-miR-302b 170 147 0.619627
hsa-miR-136 166 146 0.619627
hsa-miR-431 220 145 0.619627
hsa-miR-557 216 145 0.619627
hsa-miR-1262 105 144 0.619627
hsa-miR-154 322 144 0.666615
hsa-miR-373 168 144 0.619627
hsa-miR-583 114 144 0.619627
hsa-miR-1259 271 143 0.643121
hsa-miR-135a 264 143 0.643121
hsa-miR-135b 264 143 0.643121
hsa-miR-493 4 143 0.6910845
hsa-miR-519c-5p 79 143 0.619627
hsa-miR-520d-3p 170 143 0.619627
hsa-miR-580 307 143 0.666615
hsa-miR-196a 382 142 0.607749
hsa-miR-520a-3p 172 142 0.619627
hsa-miR-577 302 142 0.666615
hsa-miR-142-3p 384 141 0.607749
hsa-miR-378 208 141 0.619627
hsa-miR-422a 207 141 0.619627
hsa-miR-1826 387 140 0.607749
hsa-miR-302c 170 140 0.619627
(Continued)
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Table 1 | Continued
miRNA Query target
sites
Alignment
score
PhastCons
score
hsa-miR-302d 170 140 0.619627
hsa-miR-504 1 140 0.6910845
hsa-miR-521 89 140 0.619627
hsa-miR-9 234 140 0.619627
hsa-miR-942 333 140 0.666615
MOUSE OPRM1 3′-UTR
mmu-miR-540-5p 278 168.0 0.62498
mmu-miR-540-3p 395 159.0 0.584342
mmu-miR-134 403 158.0 0.584342
mmu-miR-302c 165 158.0 0.586054
mmu-miR-302d 165 151.0 0.586054
mmu-let-7i 384 149.0 0.62498
mmu-miR-139-5p 363 149.0 0.62498
mmu-let-7g 388 148.0 0.62498
mmu-miR-199a-3p 193 148.0 0.586054
mmu-miR-199b 193 148.0 0.586054
mmu-miR-496 241 148.0 0.586054
mmu-miR-532-3p 63 148.0 0.586054
mmu-let-7a 388 147.0 0.62498
mmu-let-7f 388 147.0 0.62498
mmu-let-7c 386 146.0 0.62498
mmu-miR-486 214 146.0 0.586054
mmu-miR-741 512 146.0 0.567263
mmu-miR-383 93 144.0 0.586054
mmu-miR-695 404 144.0 0.584342
mmu-let-7b 388 143.0 0.62498
mmu-let-7e 388 143.0 0.62498
mmu-miR-188-3p 64 143.0 0.586054
mmu-miR-196b 386 143.0 0.62498
mmu-miR-302b 165 143.0 0.586054
mmu-miR-323-5p 233 143.0 0.586054
mmu-miR-466f-5p 138 143.0 0.586054
mmu-miR-98 387 143.0 0.62498
mmu-miR-298 391 142.0 0.584342
mmu-miR-339-3p 71 142.0 0.586054
mmu-miR-381 528 142.0 0.590822
mmu-miR-682 186 142.0 0.586054
mmu-let-7d 388 141.0 0.62498
mmu-miR-504 57 141.0 0.586054
mmu-miR-154 321 140.0 0.62498
mmu-miR-196a 387 140.0 0.62498
mmu-miR-340-5p 527 140.0 0.590822
mmu-miR-34b-3p 367 140.0 0.62498
In order to elucidate a physiological role of let-7 in regulat-
ing MOR and opioid tolerance, we further examined the in vivo
relevance of let-7 miRs in cellular and animal models of opi-
oid tolerance. For the former, SH-SY5Y cells were treated with
morphine (1−10μM for 24–48 h) to induce cellular tolerance.
The expression of let-7 miRs was signiﬁcantly up-regulated by
chronic treatment with morphine, while the expression level of
MOR was reduced as determined by the western blotting method
(He et al., 2010) and the receptor radioligand binding using 3H-
DAMGO (He and Wang, unpublished data). Therefore, chronic
morphine treatment caused the increase of let-7 and decrease of
MOR expression during the development of opioid tolerance in
SH-SY5Y. Furthermore, the regulation of let-7 expression by mor-
phine occurred in a mouse model of opioid tolerance. Mice were
implanted s.c. with a 75-mg morphine pellet (75mg morphine
pellet/mouse, s.c.). Brain expression of let-7 increased gradually
over time after morphine treatment, temporally correlating with
the development of antinociceptive tolerance to morphine. Inter-
estingly, up-regulation of let-7 occurred in MOR-expressing cells,
but not in MOR-negative cells in mice brain cortex region as
determined by in situ hybridization (He et al., 2010). This was
in agreement with the aforementioned ﬁnding that MOR is a
direct target of let-7. In order to further examine a causative
role of let-7 in leading to opioid tolerance, we directly targeted
let-7 in the mouse model of opioid tolerance. Treatment with
the let-7 inhibitor (i.c.v.) decreased brain let-7 levels and partially
attenuated opioid antinociceptive tolerance (He et al., 2010).
Previous reports from a number of different cell lines or animal
models (e.g., Brodsky et al., 1995; Johnson et al., 2006) indi-
cated that MOR mRNA was not changed upon treatment with
morphine. We also found that the total MOR transcripts were
unchanged by morphine. For example, MOR mRNA remained
the same in SH-SY5Y cells following chronic morphine treatment.
It raised a question as to how let-7 miRs repress MOR in opioid
tolerance. We conﬁrmed that let-7 did not affect MOR mRNA
stability; however, polysome-bound MOR transcript was signiﬁ-
cantly decreased. Where is MOR mRNA hiding? It turns out that
it can be accumulated in P-bodies. So these intriguing data led us
to propose the following regulatory mechanism where upon let-7
can regulate opioid tolerance: let-7 recruits and sequesters MOR
mRNA to P-bodies that are deprived of translational machinery,
effectively reducing polysome-bound MOR mRNA and leading to
translation repression.A similar pathwaywas observed inHEK293
and HeLa cells (Pillai et al., 2005), thus translation repression
may serve as a general mechanism by let-7 to regulate its tar-
get gene expression (Figure 1). Keep in mind that let-7 activity is
turned up in opioid tolerance by up-regulation of their transcripts.
Nature works in a wonder to ensure the activity of let-7, ultimately
dampening the activity of opioids upon persistent activation.
POTENTIAL TARGET GENES OF let-7 IN OPIOID TOLERANCE
Let-7 was the ﬁrst identiﬁed human miR. Its family members
are highly conserved across species in sequence and function
(Pasquinelli et al., 2000). Major roles of let-7 include the regu-
lation of stem-cell differentiation, neuromuscular development,
and cell proliferation & differentiation (Reinhart et al., 2000;
Mansﬁeld et al., 2004; Roush and Slack, 2008). Let-7 was initially
identiﬁed as a heterochronic gene (Pasquinelli et al., 2000). In
mammals, let-7 levels increase during embryogenesis and during
brain development (Schulman et al., 2005; Wulczyn et al., 2007).
Let-7 is undetectable in human and mouse embryonic stem cells,
and the level of let-7 increases upon differentiation (Thomson
et al., 2004, 2006; Wulczyn et al., 2007). This high expression of
let-7 is then maintained in various adult tissues (Sempere et al.,
2004; Thomson et al., 2004). Furthermore, let-7 is widely viewed
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FIGURE 1 | A schematic diagram proposing a mechanism for
the regulation of target gene by let-7. Pri- and pre-let-7 are
produced and exported into the cytosol where the mature let-7
was incorporated into the RNA-induced silencing complex
(RISC). The latter recruits and sequesters target mRNA to
P-bodies that are deprived of translational machinery, effectively
reducing polysome-bound mRNA and leading to translation
repression (modiﬁed from He et al., 2010).
as a tumor suppressor miR (Boyerinas et al., 2010). There is a
clear link between loss of let-7 expression and the development of
poorly differentiated, aggressive cancers (Takamizawa et al., 2004;
Dahiya et al., 2008; Childs et al., 2009). Using the computational
algorithm TargetScan 6.02 to screen human 3′-UTR sequences
containing let-7 family miRs complementary sites, 886 conserved
targets,with a total of 989 conserved sites and111poorly conserved
sites were predicted. High-mobility group AT-hook 2 (HMGA2),
which is the top-scoring candidate gene on the list (Table 2), was
conﬁrmed as a direct let-7 target both in vitro and in vivo (Lee
and Dutta, 2007; Mayr et al., 2007; Shell et al., 2007). HMGA2
is a chromatin-associated non-histone protein capable of modu-
lating chromatin architecture and thus affecting transcription. In
addition to abundant studies onHMGA2 in embryogenesis (Zhou
et al., 1995; Sun et al., 2009) and tumorigenesis (Peng et al., 2008;
Qian et al., 2009), it would be interesting to investigate its possi-
ble involvement in opioid tolerance as a functional target gene of
let-7.
Seed pairing rules are widely used to predict functional miR
target sites. MiR-mRNA recognition requires the perfect comple-
mentarity of 6-nucleotide mRNA seed sites with the 5′ end of
miRs (positions 2–7; Bartel, 2009). However, when predictions
based on such short complementary sequences are compared to
experimental results fromproteomic studies, the false-positive and
false-negative rates appear to be above 50% (Easow et al., 2007;
Baek et al., 2008; Mourelatos, 2008; Selbach et al., 2008). Several
previous ﬁndings strongly indicated that a sizeable fraction of miR
targets do not obey the“canonical” seed rule (Ha et al., 1996; Didi-
ano andHobert, 2006; Tay et al., 2008; Stefani and Slack, 2012). For
let-7, biological studies clearly demonstrated that genetically veri-
ﬁed let-7 targets in Caenorhabditis elegans contain only imperfect
binding sites, with bulges or G·U wobble pairs in the seed region
(Vella et al., 2004). A recent study identiﬁed a new class of miR
target site nucleation bulges and an alternative mode of miR tar-
get recognition by a pivot-pairing rule (Chi et al., 2012). They
proposed a transitional nucleation model in which a transitional
nucleation state determines the binding of miRs to nucleation
2http://www.targetscan.org/
bulge mRNAs. Therefore, the identiﬁcation of non-canonical let-
7-mRNA interactions may lead to important breakthroughs in
discovering new let-7 targets and further decipher the functional
role of let-7 in opioid tolerance.
With respect to let-7 target gene identiﬁcation, another impor-
tant issue need to be addressed is the redundancy of let-7 family
members. There are 14 and 13 different let-7 family members
in mouse and human, respectively (Roush and Slack, 2008). In
human, these different members, let-7a-1, 7a-2, 7a-3, 7b, 7c, 7d,
7e, f7-1, 7f-2, 7g, 7i, miR-98, and miR-202 are located on nine dif-
ferent chromosomes (Ruby et al., 2006). While let-7 was initially
viewed as one single activity, emerging data suggest that the let-
7 family contains miRs with different activities (i.e., targets). For
example, it has been reported that let-7b∗ was highly expressed but
let-7e∗ was drastically reduced inmalignantmesothelioma (Guled
et al., 2009). So the question remains as whether individual let-7
family member with its own expression pattern exerts specialized
function during opioid tolerance development.
CONCLUSION AND FUTURE DIRECTIONS
Opioid tolerance, even to the analgesic actions of these drugs, is
likely not caused by a single mechanism; rather an intricate neu-
ronal circuitry involvingmultiplemechanismsmayultimately lead
to the expression of tolerance seen in humans. Regulation of opi-
oid tolerance, through MOR or other mechanisms, represents one
of these mechanisms. What is not known is how many miRs are
involved. Existing literature onmiR-relatedmechanisms of opioid
tolerance is sparse. A typical study in miR research ﬁeld tends to
survey transcript levels of miRs in a disease state (Zheng et al.,
2010). For example, morphine-induced up-regulation of miR-
15b in human monocyte-derived macrophages (Dave and Khalili,
2010), while miR-133b was decreased by morphine in zebraﬁsh
embryos (Sanchez-Simon et al., 2010). It is often extremely difﬁ-
cult to identify a casual relationship. Furthermore, moving from a
cell line to in vivo relevance is another big hurdle to overcome.
In the case of let-7 miRs, it was identiﬁed as a critical regulator
of both human and mouse MOR. Moreover, it was demonstrated
to be relevant for both cellular opioid tolerance as well as animal
models of opioid tolerance (He et al., 2010). Let-7 represents one
of several miRs contributing to opioid tolerance. For example, it
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Table 2 |Top 100 predicted targets of let-7 miRNAs ranked by total context score (TargetScan 6.0, http://www.targetscan.org/.)
Target gene (1–50) Total context score Aggregate PCT Target gene (51–100) Total context score Aggregate PCT
Hmga2 −1.08 >0.99 Map4k3 −0.46 0.96
Fignl2 −1.07 >0.99 Tmem211 −0.46 <0.1
Lin28b −0.98 >0.99 Zfp583 −0.46 0.96
Trim71 −0.98 >0.99 Dtx2 −0.46 0.99
Zc3hav1l −0.85 0.86 Diap2 −0.46 0.98
Fign −0.84 >0.99 Pgrmc1 −0.46 0.9
Nr6a1 −0.8 >0.99 Pars2 −0.46 <0.1
2200002K05Rik −0.7 >0.99 Cd200r1 −0.45 0.94
Skil −0.67 >0.99 Abt1 −0.45 <0.1
Igdcc3 −0.65 >0.99 Acot11 −0.45 0.5
Thrsp −0.62 <0.1 Kcnj11 −0.45 0.81
Prtg −0.61 >0.99 Zfp248 −0.45 <0.1
Slc5a9 −0.6 0.83 Bcl2l13 −0.44 <0.1
Tgfbr1 −0.58 >0.99 Gatm −0.44 0.95
Yod1 −0.58 >0.99 Hic2 −0.44 >0.99
Smarcad1 −0.57 0.96 Ccnj −0.44 0.97
Gab2 −0.57 0.6 Arid3a −0.44 >0.99
Ngly1 −0.54 <0.1 Hand1 −0.44 0.98
Kctd21 −0.54 0.98 Igf1r −0.44 >0.99
Dna2 −0.53 <0.1 Rpusd3 −0.43 0.59
Ppp1r15b −0.53 >0.99 Pbx3 −0.43 0.99
Nphp3 −0.53 0.94 Zmat4 −0.43 0.97
Vezt −0.52 <0.1 Tmem164 −0.43 <0.1
Suv39h2 −0.51 0.44 Bcat1 −0.43 0.99
Gdf6 −0.5 0.98 Pxt1 −0.43 <0.1
Brwd1 −0.5 <0.1 Als2cl −0.43 <0.1
Coil −0.49 0.97 9930012K11Rik −0.42 0.94
Lrig3 −0.49 0.89 Atg10 −0.42 <0.1
Hoxb1 −0.49 0.98 Limd2 −0.42 0.94
Zcchc9 −0.48 <0.1 Zfp341 −0.42 <0.1
B3gnt7 −0.48 0.76 Fam103a1 −0.42 0.87
Entpd7 −0.48 <0.1 Med28 −0.42 0.56
Acvr1c −0.48 0.99 Smug1 −0.42 <0.1
Lrig2 −0.48 0.99 Trpm3 −0.42 <0.1
Bzw1 −0.48 >0.99 Fras1 −0.42 0.96
Gnptab −0.48 0.98 Uhrf2 −0.41 0.86
Wdr41 −0.48 <0.1 Cdc25a −0.41 0.8
Cdc34 −0.47 0.99 Igf2bp1 −0.41 >0.99
Slc35d2 −0.47 0.98 Cep110 −0.41 0.94
Dclre1b −0.47 0.12 Mrps33 −0.41 <0.1
Hif1an −0.47 0.61 Tnfsf10 −0.41 <0.1
Zfp322a −0.47 0.82 Arhgap28 −0.41 0.98
Adrb2 −0.47 0.98 Apbb3 −0.41 0.98
Tmprss11f −0.47 0.92 Fndc3a −0.41 0.97
Ddx19b −0.47 0.98 Col1a2 −0.41 0.97
Ddx19a −0.47 0.98 Gemin7 −0.41 <0.1
Galnt1 −0.47 >0.99 Wnt9a −0.41 0.99
Greb1l −0.47 0.99 Igf2bp2 −0.41 0.93
Ercc6 −0.47 0.98 Tmem2 −0.41 0.98
Ddi2 −0.46 0.89 Zfp879 −0.41 0.35
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was found miR-23b could interact with the MOR 3′-UTR via a
K box motif (5′-UGUGAU-3′) in SH-SY5Y and mouse P19 cells
(Wu et al., 2008, 2009).
While MOR is involved in the development of morphine toler-
ance, it is not the only target for the action of miRs in opioid tol-
erance (Matthes et al., 1996; Sora et al., 1997).With the increasing
understanding of miRs in epigenetic regulation, further research is
needed to identify other target genes of miRs (including let-7). A
number of receptors, ion channels, andprotein kinases,whichhave
been implicated in opioid tolerance, such as the NMDA receptors,
PKC,andCaMKII (Kieffer andEvans, 2002;Wang andWang,2006;
Ueda and Ueda, 2009) may become potential targets for let-7.
In summary,miR-mediatedmechanisms provide a novel direc-
tion toward unraveling the complex mechanisms involved in the
development of opioid tolerance. These studies will enrich our
knowledge on basic principles of neuronal and behavioral adap-
tation in opioid tolerance, and eventually lead to novel design and
development of pharmacological treatments for opioid tolerance.
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